About: DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Sector: Healthcare
Industry: Biotechnology
Latest price: $10.29 (-3.38%)
DBVT NASDAQ DBV Technologies
DBV Technologies share price
Atividade de preço de DBVT
Último preço
$ 10,290
Variação (24h)
-0,36 USD (3,38%)
Volume
1.03M
Volume (média 4 sem.)
-
Abertura
$ 9,35
Variação do dia
$ 9,34 - $ 10,75
Fechamento anterior
$ 10,65
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
DBVT price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals